Opinion|Videos|November 1, 2024
Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Is the process different/similar for patients who might be receiving non-BCMA targeted bispecific vs BCMA-bispecific?
- Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step up dosing, premedication/prophylaxis, etc.
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5